FSTL1 and cardiac hypertrophy: In an ischemia/reperfusion-induced myocardial injury model, systemic or intracoronary injection of FSTL1 reduced the expression of inflammatory cytokines such as TNF-α and IL-6, thereby improving cardiac hypertrophy and dysfunction [27].